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Introduction {#sec1}
============

First discovered in Africa in 1947 ([@bib9], [@bib10]), Zika virus (ZIKV) is a positive-sense enveloped flavivirus that is primarily transmitted by the *Aedes aegypti* mosquito ([@bib28]). Unlike other flaviviruses, ZIKV is capable infecting the male reproductive organs, leading to testicular atrophy ([@bib16], [@bib30], [@bib50]) and sexual transmission ([@bib20]). Most infections with this virus are asymptomatic ([@bib12]), and the majority of symptomatic infections result in a mild and self-limiting febrile illness ([@bib46], [@bib2]). Rare cases of more severe illness have been reported including Guillain-Barré syndrome (GBS), marked by subacute flaccid paralysis ([@bib36], [@bib22]) in infected adults, and infection of pregnant women has been associated with severe birth defects, including congenital malformations and severe birth defects in newborns ([@bib54], [@bib51], [@bib43]).

Upon ZIKV infection, ZIKV is present in a variety of tissues and body fluids including the central nervous system ([@bib49]), saliva ([@bib32]), blood ([@bib33]), urine ([@bib57]), and semen ([@bib1]), many of which are unique among flaviviruses. Similar to other flaviviruses, ZIKV targets dendritic cells and macrophages in the skin and other tissues for replication ([@bib55], [@bib23], [@bib18]), and replication of the virus in the testes ([@bib16], [@bib30], [@bib50]) and brain ([@bib26], [@bib31]) results in apoptosis of important cell types driving pathogenesis. This difference in tissue tropism for ZIKV compared with related flaviviruses has led to significant efforts to identify the entry receptor for this virus. One of the leading candidate proteins implicated as facilitating viral entry is a member of the TAM family of receptor tyrosine kinases, Axl ([@bib18], [@bib29], [@bib39], [@bib31], [@bib42]). However, work from this group ([@bib21]) and others ([@bib52]) has shown that Axl is dispensable in a murine model of ZIKV infection, and genetic ablation of Axl in human neural progenitor cells and cerebral organoids does not prevent ZIKV infection ([@bib53]).

ZIKV infects several cell types that express high levels of Axl ([@bib25], [@bib35], [@bib30], [@bib48], [@bib40]), and signaling of this protein contributes to infection of astrocytes by downregulating type I interferon (IFN) signaling ([@bib8]). Axl is a member of the TAM family of tyrosine kinase receptors. These receptors bind the ligands, Gas6 and Protein S, which recognize phosphatidylserine present on enveloped viruses and dying cells ([@bib45], [@bib25]). Type I IFN signaling upregulates TAM receptors, which are part of a negative feedback loop for inflammatory responses and inhibits the Toll-like receptor pathway ([@bib41], [@bib7]). In dendritic cells, this inhibition is dependent on a physical interaction with the type I IFN receptor (Ifnar) ([@bib41]). In addition, these receptors contribute to the clearance of apoptotic cells and the differentiation of natural killer cells ([@bib3], [@bib5], [@bib6], [@bib38]). ZIKV infection is controlled by type I IFN signaling ([@bib24]) and is capable of using its NS5 protein to degrade human STAT2 and inhibit this signaling, but not mouse STAT2 ([@bib17]), requiring the use of immune-deficient mice for assessment of infection in the mouse model. To further assess the role of Axl, we generated an Ifnar/Axl double knockout mouse, which is susceptible to infection, and tested ZIKV replication and pathogenesis in this mouse model.

Results {#sec2}
=======

The TAM Receptor, Axl, Is Not Required for Replication of ZIKV *In Vivo* but Is Involved in Viral Pathogenesis {#sec2.1}
--------------------------------------------------------------------------------------------------------------

To probe the function of the TAM receptor Axl in a holistic murine infection model lacking this protein (*Ifnar*^*−/−*^*Axl*^*−/−*^), we bred together two existing mouse models. The first, an IFN-αβ receptor knockout (*Ifnar*^*−/−*^), will render this model susceptible to ZIKV infection, and the second, an Axl knockout (*Axl*^*−/−*^), will allow us to probe the role of Axl in ZIKV pathogenesis and replication in specific tissues ([Figure 1](#fig1){ref-type="fig"}A). To determine if Axl is involved in replication of ZIKV in this model, we subcutaneously inoculated *Ifnar1*^*−/−*^*Axl*^*−/−*^ and *Ifnar1*^*−/−*^ mice and show that Axl is not required for ZIKV replication in the blood at days 2, 4, and 6 as measured by qRT-PCR ([Figure 1](#fig1){ref-type="fig"}B), in the brain at day 6 as measured by qRT-PCR ([Figure 1](#fig1){ref-type="fig"}C), or in plaque assay ([Figure 1](#fig1){ref-type="fig"}D).Figure 1The TAM Receptor Axl Is Not Required for Replication of ZIKV *In Vivo* but Is Involved in Viral Pathogenesis(A--H) (A--F) Six-week old or (G and H) three-week old *Ifnar1*^*−/−*^ or *Ifnar1*^*−/−*^*Axl*^*−/−*^ mice were subcutaneously infected via footpad injection with 10^5^ plaque-forming unit Cambodian strain of ZIKV. (A) Diagram of Axl knockout mouse model describing the purpose of gene ablation. (B) Whole blood was collected at days 2, 4, and 6 post-ZIKV infection from both groups and analyzed by qRT-PCR. (C and D) At day 6, when mice begin to show viral pathogenesis, mice were sacrificed, brains were collected, and ZIKV levels were analyzed using (C) qRT-PCR and (D) plaque assay. (E and G) Both groups were weighed daily for two weeks or until sacrificed due to severe pathogenesis, and data were graphed as a percentage of original body. (F and H) Mice were also monitored for survival for two weeks after ZIKV infection. ZIKV RNA levels were normalized to mouse β-actin (ACTB) RNA levels. (n = 8--10/group for each genotype). Significance was tested by (B) two-way ANOVA with a post-hoc Tukey test, (C and D) Student\'s t test, or (F and H) log rank (Mantel-Cox) test. Error bars represent SEM.

Interestingly, in mice lacking Axl expression ZIKV pathogenesis is significantly decreased, with infected animals showing a slight decrease in weight around days 6--8 ([Figure 1](#fig1){ref-type="fig"}E) but most recovering fully, whereas the virus is 100% lethal in mice expressing Axl ([Figure 1](#fig1){ref-type="fig"}F). The pathogenesis in this model appeared to be driven by replication of virus in the brain, as the mice that died had hindlimb paralysis and unsteadiness on their feet. This phenotype appears to be age dependent, as Axl knockout weanling mice (3 weeks old) show no difference in ZIKV pathogenesis compared with those expressing Axl ([Figures 1](#fig1){ref-type="fig"}G and 1H). These data indicate that although ZIKV does not require Axl to replicate in the mouse model, this protein is important for driving severe disease *in vivo*.

Axl Expression Is Important for IL-1β Expression during ZIKV Infection {#sec2.2}
----------------------------------------------------------------------

To attempt to determine the mechanism underlying the increased pathogenesis of ZIKV in Axl-competent mice, we collected brains from *Ifnar1*^*−/−*^ and *Ifnar1*^*−/−*^*Axl*^*−/−*^ mice and isolated RNA to determine the expression of important inflammatory cytokines during viral infection. Using qRT-PCR, we show that the levels of transforming growth factor-β, tumor necrosis factor-α, IFN-γ, and IL-6 are not different between *Axl*^*−/−*^ and *Axl* wild-type mice ([Figures 2](#fig2){ref-type="fig"}B--2E), but that *Ifnar1*^*−/−*^*Axl*^*−/−*^ mice had significantly lower pro-IL-1β levels when compared with *Ifnar1*^*−/−*^ mice ([Figure 2](#fig2){ref-type="fig"}A). Interestingly, no differences in the expression of inflammatory cytokines were observed between 3-week-old IFNAR^−/−^Axl^−/−^ mice and Axl-competent mice of the same age during ZIKV infection ([Figure S1](#mmc1){ref-type="supplementary-material"}).Figure 2Axl Expression Is Important for IL-1β Expression during ZIKV InfectionSix-week old *Ifnar1*^*−/−*^ or *Ifnar1*^*−/−*^*Axl*^*−/−*^ mice were subcutaneously infected via footpad injection with 10^5^ plaque-forming unit Cambodian strain of ZIKV.(A--E) At day 6, when mice begin to show viral pathogenesis, they were sacrificed, brains were collected and (A) pro-IL-1β, (B) TGF-β, (C) TNF-α, (D) IFN-γ, and (E) IL-6 levels were analyzed using qRT-PCR. ZIKV RNA levels were normalized to mouse β-actin (ACTB) RNA levels. Data are expressed as a percentage of the average expression in the *Ifnar1−/−* group. Significance was tested using Student\'s t test (n = 8--10/group for each genotype).

To determine if this increased inflammatory response in 6-week-old Axl knockout mice is a result of enhanced inflammatory cell recruitment or proliferation in the brains of ZIKV-infected mice, we examined the number of immune cells in the brain at day 6 of ZIKV infection using flow cytometry ([Figure S2](#mmc1){ref-type="supplementary-material"}). There is a robust expansion or infiltration of monocytes ([Figure 3](#fig3){ref-type="fig"}A), neutrophils ([Figure 3](#fig3){ref-type="fig"}B), macrophages ([Figure 3](#fig3){ref-type="fig"}C), dendritic cells ([Figure 3](#fig3){ref-type="fig"}D), microglia ([Figure 3](#fig3){ref-type="fig"}E), and both CD4^+^ ([Figure 3](#fig3){ref-type="fig"}G) and CD8^+^ ([Figure 3](#fig3){ref-type="fig"}H) T cells in infected mice, whereas there are no significant differences between *Ifnar1*^*−/−*^ and *Ifnar1*^*−/−*^*Axl*^*−/−*^ mice ([Figure 3](#fig3){ref-type="fig"}). Intriguingly, there was a trend toward slightly fewer CD11c^+^ activated microglia in *Ifnar1*^*−/−*^*Axl*^*−/−*^ mice ([Figure 3](#fig3){ref-type="fig"}F), but this difference was not significant. IL-1β is highly expressed during apoptosis, so we hypothesized that Axl could instead be playing a role in driving apoptosis during ZIKV infection.Figure 3Axl Expression Does Not Drive Differences in Immune Cell Infiltration during ZIKV InfectionSix-week old *Ifnar1*^*−/−*^ or *Ifnar1*^*−/−*^*Axl*^*−/−*^ mice were subcutaneously infected via footpad injection with 10^5^ plaque-forming unit Cambodian strain of ZIKV.(A--H) At day 6, when mice begin to show viral pathogenesis, mice were sacrificed, brains were collected, and (A) monocytes, (B) neutrophils, (C) macrophages, (D) dendritic cells, (E) microglia, (F) activated microglia, (G) CD4^+^ T cells, and (H) CD8^+^ T cells were analyzed using flow cytometry. Data are expressed as total number of cells present in the brain. Significance was tested by two-way ANOVA with a post-hoc Tukey test. No significant differences were detected among any groups. Error bars represent SEM (n = 8/group for each infected group and n = 2/group for each uninfected group).

Axl Drives Apoptosis in Microglia in the Brains of ZIKV-Infected Mice {#sec2.3}
---------------------------------------------------------------------

To examine if Axl plays a role in driving apoptosis in the 6-week-old animals, we dissected brains from ZIKV-infected *Ifnar1*^*−/−*^ or *Ifnar1*^*−/−*^*Axl*^*−/−*^ mice at day 6, and performed a TUNEL assay, which selectively marks cells with breaks in DNA indicating apoptosis, on fixed brain sections. It is evident that Axl-competent mice have markedly increased apoptosis across several regions of the brain, including the ventral striatum ([Figure 4](#fig4){ref-type="fig"}A), the cerebellum ([Figure 4](#fig4){ref-type="fig"}B), and the hippocampus ([Figure 4](#fig4){ref-type="fig"}C).Figure 4Axl Drives Apoptosis in the Brain of ZIKV-Infected MiceSix-week old *Ifnar1*^*−/−*^ or *Ifnar1*^*−/−*^*Axl*^*−/−*^ mice were subcutaneously infected via footpad injection with 10^5^ plaque-forming unit Cambodian strain of ZIKV.(A--C) At day 6, when mice begin to show viral pathogenesis, mice were sacrificed, brains were collected, fixed in buffered formalin, and prepared for histology. Slides were stained using the TUNEL assay, and the entire brain was imaged at 20×. Shown are (A) the ventral striatum, (B) the cerebellum, and (C) the hippocampus (n = 4/group for each genotype). Scale bar, 500 μM in main image and 100 μM in inset image.

By co-staining these tissue sections with TUNEL and NeuN (neurons, [Figure 5](#fig5){ref-type="fig"}A), glial fibrillary acidic protein (GFAP) (astrocytes, [Figure 5](#fig5){ref-type="fig"}B), or Iba1 (microglia, [Figure 5](#fig5){ref-type="fig"}C), we can clearly show that microglia represent the main apoptotic cell type present in the brain. As these cells are capable of phagocytosing dead cells, we cannot rule out the possibility that some of the microglial cells appear TUNEL positive owing to phagocytosis of other cell types; however, the majority of these cells show TUNEL staining in the nucleus (co-localizing with DAPI staining) and not in the cytoplasm ([Figure 5](#fig5){ref-type="fig"}C), which indicates that these cells are undergoing apoptosis themselves. When TUNEL^+^ microglia were quantified, significantly more TUNEL^+^ microglia were observed in the brains of Axl-competent mice compared with Axl^−/−^ mice ([Figure 5](#fig5){ref-type="fig"}D), further suggesting a role of Axl in driving apoptosis in these cells.Figure 5ZIKV Induces Apoptosis in MicrogliaSix-week old *Ifnar1*^*−/−*^ or *Ifnar1*^*−/−*^*Axl*^*−/−*^ mice were subcutaneously infected via footpad injection with 10^5^ plaque-forming unit Cambodian strain of ZIKV.(A--C) At day 6, when mice begin to show viral pathogenesis, mice were sacrificed, brains were collected, fixed in buffered formalin, and prepared for histology. Slides were stained using the TUNEL assay and antibodies toward (A) NeuN (neurons), (B) GFAP (astrocytes), or (C) Iba1 (microglia) and imaged at 20×. Insets are digitally enlarged by 3× to show individual cells. Scale bar is 100 μM in main image. Shown is representative image from *Ifnar1*^*−/−*^ mice.(D) Percent microglia that were TUNEL+ were quantified and graphed from two to three random fields in the brains of each genotype. Significance was tested by two-way ANOVA. Error bars represent SEM (n = 4/group for each genotype).

The canonical apoptosis pathway is caspase 3 dependent and can be either extrinsic through death receptor (like tumor necrosis factor-related apoptosis-inducing ligand receptor) signaling and caspase 8, or intrinsic through mitochondrial-associated Bcl-2 homology proteins and caspase 9. Downstream of both these pathways is cleavage of poly (ADP-ribose) polymerase (PARP), which is responsible for repairing DNA. Six-week-old Axl-deficient mice have significantly lower levels of cleaved PARP shown by western blot analysis of whole ZIKV-infected brain homogenates of ZIKV-infected mice, and there was significantly higher caspase 8 and cleaved caspase 9, and a trend toward higher caspase 3, cleaved caspase 3, and caspase 9, in the *Ifnar1*^*−/−*^ mice when compared with the Axl-deficient mice, which indicates that the observed apoptosis is induced both through the intrinsic and extrinsic pathways ([Figures 6](#fig6){ref-type="fig"} and [S3](#mmc1){ref-type="supplementary-material"}). Caspase 12 is involved in a less common apoptotic pathway, and whereas less caspase 12 expression was seen in the Axl-deficient group ([Figure 6](#fig6){ref-type="fig"}H), no change in cleaved caspase 12 was observed ([Figure 6](#fig6){ref-type="fig"}I). This suggests that Axl signals through a caspase-dependent PARP-dependent manner leading to apoptosis in microglia.Figure 6ZIKV Induces Apoptosis by a PARP-Dependent Caspase-Dependent MechanismSix-week old *Ifnar1*^*−/−*^ or *Ifnar1*^*−/−*^*Axl*^*−/−*^ mice were subcutaneously infected via footpad injection with 10^5^ plaque-forming unit Cambodian strain of ZIKV.(A--J) At day 6, when mice begin to show viral pathogenesis, they were sacrificed, brains were collected in radioimmunoprecipitation assay (RIPA) buffer with protease inhibitor, and a western blot was performed. Membrane was probed with antibodies toward proteins involved in apoptosis. Protein expressions of (A) PARP, (B) cleaved PARP, (C) caspase 3, (D) cleaved caspase 3, (E) caspase 8, (F) caspase 9, (G) cleaved caspase 9, (H) caspase 12, and (I) cleaved caspase 12 were quantified using ImageJ. Data shown are representative of at least two independent experiments. Significance was tested with two-tailed Mann-Whitney U test. Error bars represent SEM (n = 4/group for each genotype).

Discussion {#sec3}
==========

Axl has been shown to be involved in the immune response during ZIKV infection and has been implicated as an entry factor for specific cell types. To further examine the role of Axl in replication and pathogenesis in mice, we generated a mouse lacking Axl that was also deficient in the Ifnar protein, rendering these animals highly susceptible to ZIKV infection. Using this model, we demonstrate that although, similar to our previous work, ZIKV replication levels are unaffected by the lack of Axl, the loss of this molecule protected mice from severe viral pathogenesis in the brain. This protection coincided with significantly lower inflammatory pro-IL-1β expression and a decrease in apoptosis, specifically in glial cells, in the brains of Axl-deficient mice. These data suggest that Axl present on microglia is involved in facilitating ZIKV pathogenesis by inducing apoptosis in these cells.

Small-molecule inhibition of Axl in human cell lines ([@bib18], [@bib29], [@bib39], [@bib31], [@bib42]), small interfering RNA knockdown of Axl human alveolar basal epithelial carcinoma cells (A549) ([@bib18]), and CRISPR knockout of Axl in human cervical adenocarcinoma cells (HeLa) ([@bib42]), a human glioblastoma line (U87) ([@bib39]), a human microglial cell line (CHME3) ([@bib31]), and human embryonic kidney cells (293T) ([@bib29]) has been shown to block or reduce ZIKV infection, but Axl is not necessary for replication of ZIKV in the mouse model ([@bib21], [@bib52]). Intriguingly, our group has shown that murine Axl is capable of acting as an entry factor by using a transcomplementation assay ([@bib21]). This raises the possibility that this protein is important for entry into specific cell types, but these cell types are not a major contributor to overall ZIKV replication in the mouse model. Meertens et al. demonstrated that Axl can mediate ZIKV infection of astrocytes and microglia *in vitro* and that the subsequent signaling in these cells through Axl dampens type I IFN signaling and increases viral replication in glial cells. As the mouse model that we generated is deficient in Ifnar, any phenotype observed in these mice is independent of Axl\'s role in the regulation of type I IFNs. Therefore the lack of difference in viral titer suggests that if Axl is indeed involved in entry to these cells, these cells do not represent a major source of viral replication in the mouse model. The data presented here are consistent with Axl facilitating entry into microglia and indicate that the inflammatory response by these cells is critical for the pathogenesis of ZIKV in the brain.

The apoptosis observed in our histology (TUNEL) and western blot (cleaved PARP) experiments appears to be Axl dependent. Canonical apoptosis is induced through an extrinsic pathway, dependent on death ligands or receptors and caspase 8, or an intrinsic pathway, dependent on mitochondrial changes and caspase 9 ([@bib13]). To determine if this phenomenon is due to an increase in components of canonical apoptosis pathways, we performed western blot analysis of various proteins involved in intrinsic and extrinsic apoptosis. Interestingly, Axl-deficient mice had slightly lower levels of these proteins when compared with Axl-competent mice. Axl expression appears to increase both intrinsic and extrinsic apoptosis during ZIKV infection, and it is possible that the difference in apoptosis is caused by a difference in viral entry and infection in a specific cell type, perhaps glial cells, or the mechanistic role of Axl in specific functions of microglia.

ZIKV is capable of targeting and replicating in both developing neural stem cells and to a lesser extent in mature neurons ([@bib35], [@bib49], [@bib37]). In addition, the symptoms of GBS that have been associated with acute ZIKV infection are likely related to infection or autoimmune-mediated death of neurons or glial cells ([@bib11], [@bib47]). Susceptible knockout mice infected with ZIKV are marked by acute and severe neuropathology and hindlimb paralysis ([@bib27]), and the data here indicate that this pathogenesis is related to Axl expression and apoptosis of microglia. Interestingly, microglia have been shown to undergo a process termed *phagoptosis*, in which they become activated and phagocytose live neurons, or other cells ([@bib4]). This process is directly related to the expression of TAM receptors including Axl ([@bib14]). It is possible that the neuropathogenesis observed during ZIKV infection could be related to the phagoptosis of ZIKV-infected neurons by activated microglia.

It is also possible that the increase in pathogenesis observed in the presence of Axl is related to uncontrolled inflammatory responses. Neuropathogenesis in Japanese encephalitis virus, another flavivirus, has been attributed to inflammation in the brain, including excessive IL-1β expression ([@bib34]), and expression of this inflammatory cytokine is also responsible for pathogenesis in the brains of patients infected with HIV ([@bib56]) and Alzheimer disease ([@bib44]). Counterintuitively, Axl kinase signaling has been shown to suppress inflammation and IL-1β expression ([@bib15], [@bib19]), but we hypothesize that the difference observed in inflammation and pathogenesis in our experiments is due to decreased infection of, or phagocytosis of virus and virally infected cells by, microglia lacking Axl. This would be consistent with studies showing that entry via clathrin-mediated endocytosis of ZIKV into glial cells is decreased when Axl is blocked ([@bib31]).

Taken together, these data suggest an important role for Axl in the pathogenesis of ZIKV in the brain. In addition, using a susceptible mouse model lacking Ifnar we further corroborate our previous work showing that Axl is not necessary for ZIKV infection. The similarity between ZIKV levels in wild-type and Axl knockout mice indicate that, whereas Axl is important for entry into cell types, like microglia, that are crucial for viral neuropathogenesis, it is dispensable for entry and replication into cell types that are major producers of virus *in vivo.* Therefore pharmacological agents that have been developed to target Axl as therapeutics for ZIKV could represent an effective strategy for combatting ZIKV pathogenesis.

Limitations of Study {#sec3.1}
--------------------

These experiments were performed in IFNAR knockout mice, which allows us to not only infect with ZIKV and observe IFN-independent effects of Axl but also reduce the physiological relevance of this model. We have not fully characterized the phenotype of microglia, astrocytes, and neurons in the IFNAR knockout model, and it is possible that some other virally independent phenotype could drive the striking difference in survival that we observed. It would also be particularly interesting to generate microglia-specific (or other cell-type-specific) knockouts of Axl to observe if these effects are driven by Axl on these cells or on others. This study uses the pre-pandemic Cambodian strain of ZIKV, and it is possible that this phenotype would change with a pandemic strain. We did infect these mice with a pandemic Mexican strain of virus (MEX2-81), but we did not observe the same severe pathogenesis in IFNAR knockout mice.

Methods {#sec4}
=======

All methods can be found in the accompanying [Transparent Methods supplemental file](#mmc1){ref-type="supplementary-material"}.
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Document S1. Transparent Methods and Figures S1--S3
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